Renate Panzer‐Grümayer

Author

Also Known As

Felix Niggli, Renate E Panzer-Grümayer, Renate E Panzer-Grümayer, Renate Panzer-Grumayer, Renate Panzer-Grümayer, Renate Panzer-Grümayer, Renate Panzer‐Grümayer

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

St Anna Children's Hospital St. Anna Children's Cancer Research Institute University Hospital Schleswig-Holstein University of Lübeck Medizinische Hochschule Hannover

About

Renate Panzer‐Grümayer is an author at St Anna Children's Hospital specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	478
2	Cell Biology	5	5	108
3	Health Sciences	1	1	95
4	Natural Sciences	1	1	19
5	Cellular Physiology	1	1	34

Renate Panzer‐Grümayer

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Valentino Conter, Claus R. Bartram, Maria Grazia Valsecchi, Blood	2010	778
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study Martin Schrappe, Maria Grazia Valsecchi, Claus R. Bartram, Blood	2011	431
<i>IKZF1</i><sup>plus</sup>Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Martin Stanulla, Elif Dağdan, Markéta Žaliová, Journal of Clinical Oncology	2018	285
Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia Sarah Ebinger, Erbey Ziya Özdemir, Christoph Ziegenhain, Cancer Cell	2016	277
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group Trudy Buitenkamp, Shai Izraeli, Martin Zimmermann, Blood	2013	242
Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options Ute Fischer, Michael Förster, Anna Maria Rinaldi, Nature Genetics Therapeutic OptionsTumor BiologyHematological MalignancyMedicineImmunology	2015	234
Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group Cornelia Eckert, Günter Henze, K. Seeger, Journal of Clinical Oncology	2013	164
Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster (ALL-BFM) Trials Andishe Attarbaschi, Georg Mann, Renate Panzer‐Grümayer, Journal of Clinical Oncology	2008	111
ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling Lilian Kuster, Reinhard Grausenburger, Gerhard Fuka, Blood	2011	100
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000) Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaPurpose Delayed IntensificationPharmacotherapyMetronomic ChemotherapyPre-clinical Pharmacology	2017	95

Page 1